Guided Therapeutics Inc   (GTHP)
Other Ticker:  
Price: $0.1435 $-0.01 -8.013%
Day's High: $0.1435 Week Perf: -4.9 %
Day's Low: $ 0.14 30 Day Perf: -18 %
Volume (M): 27 52 Wk High: $ 0.30
Volume (M$): $ 4 52 Wk Avg: $0.18
Open: $0.14 52 Wk Low: $0.06

 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 51
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Guided Therapeutics Inc
Guided Therapeutics Inc is a medical device company that specializes in the development and commercialization of non-invasive diagnostic devices. The company's flagship product is the LuViva Advanced Cervical Scan, which is designed to detect cervical disease and precancerous conditions in women.

Guided Therapeutics' LuViva technology utilizes a non-invasive method that combines spectroscopy and advanced optics to provide immediate results and improve the accuracy of cervical disease detection. The device can distinguish between normal and abnormal cervical tissue, enabling healthcare providers to make timely and educated decisions regarding patient care.

The company is dedicated to improving women's health and reducing the number of unnecessary biopsies and procedures associated with cervical disease. By providing a non-invasive, quick, and accurate diagnostic solution, Guided Therapeutics aims to transform the way cervical disease is detected and managed.

Guided Therapeutics Inc has received regulatory approvals for its product in various countries and continues to expand its commercial reach globally. The company also actively engages in research and development to enhance its existing technology and explore new applications in the field of non-invasive diagnostics.

   Company Address: 5835 Peachtree Corners East Peachtree Corners 30092 GA
   Company Phone Number: 242-8723   Stock Exchange / Ticker: GTHP
   GTHP is expected to report next financial results on March 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Guided Therapeutics Inc

Remarkable Transformation: Company's Evanescence of Losses Turns Heads in July-September 2023 Span!

An Encouraging Quarter for Guided Therapeutics Inc in the Stock Market
Guided Therapeutics Inc, a prominent player in the medical device industry, recently released its financial results for the quarter ending September 30, 2023. The company's performance showed significant improvements, which have been well-received by investors. Let's dive into the key highlights and understand the implications for the stock market.
One of the most striking elements in Guided Therapeutics Inc's report is the decrease in the loss per share compared to both the previous year and the preceding quarter. For the July to September 2023 span, the company reduced its loss per share to $-0.01, a significant improvement from $-0.03 a year ago. This reduction indicates that the company is on an upward trajectory and is successfully working towards improving its financials.

Guided Therapeutics Inc

Guided Therapeutics Inc Achieves Impressive Revenue Growth in Q2 2023 Despite Net Losses

Guided Therapeutics Inc Reports Strong Revenue Growth in Second Quarter of 2023 Despite Losses
Guided Therapeutics Inc, a medical equipment and supplies company, recently announced a significant increase in revenue for the second quarter of 2023. The company reported a robust revenue advance of 780% year on year, reaching $0.04 million. However, Guided Therapeutics Inc also experienced a net loss of $-0.03 million during the same period.
While the company's revenue growth outpaced that of its peers in the Medical Equipment & Supplies industry, with most companies in the sector recording an average top-line advance of 4.48%, Guided Therapeutics Inc faced a financial setback in terms of net profit. The company's deficit per share increased from $-0.02 in the previous quarter to $-0.03, and revenue surged by 100% from $0.02 million.

Guided Therapeutics Inc

Guided Therapeutics Inc Posts Impressive Turnaround with Dramatic Profitability Boost Amid Revenue Decline

Guided Therapeutics Inc (GTK) has turned the corner on its financials for the fiscal interval ending March 31 2023, with significant improvements to both earnings per share and loss per share. With a decrease from $-0.04 to $-0.02 in loss per share, and an improvement from $-0.03 to positive earnings per share, it appears that the company has implemented an effective strategy to increase profitability.
Despite a sharp decline in revenue, down 85.135% from $0.15 million to $0.02 million in the comparable financial reporting period a year prior and sequentially from $0.00 million, there are reasons to be optimistic about the company's future. GTK's net deficit of $-0.934 million is only slightly larger than the figure from the prior year ($-0.862 million), meaning that the company's cost-cutting measures are having a positive impact on the bottom line.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com